New drug combo shows promise for Tough-to-Treat endometrial cancer
NCT ID NCT03526432
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times
Summary
This phase II trial is testing a combination of two drugs—atezolizumab (an immunotherapy) and bevacizumab (a drug that cuts off blood supply to tumors)—in 110 women with advanced, recurrent, or persistent endometrial cancer. The goal is to see how many patients experience tumor shrinkage or disappearance. Participants receive both drugs by IV every three weeks until the disease worsens or side effects become too severe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Atezolizumab and Bevacizumab (immunotherapy and anti-angiogenic drug combination)
- What this could lead to
- If successful, this combination could offer a new treatment option for women with advanced endometrial cancer that has not responded to standard chemotherapy.
- What could go wrong
- This is a phase II trial with a single group and no placebo, so results are preliminary. The combination may not improve outcomes and could cause side effects like high blood pressure or immune-related reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Stephenson Cancer Center, University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73117, United States
-
UAB Women and Infants Center
Birmingham, Alabama, 35233, United States
-
Washington University School of Medicine
St Louis, Missouri, 63108, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- What raises endometrial cancer risk in black women? a study digs in
- Can immunotherapy plus hormones spare the womb in early endometrial cancer?
- Can a new drug tackle Hard-to-Treat gynecologic cancers?
- Can a pill restore the Body's tumor suppressor to fight multiple cancers?
- Could gentle yoga and breathing ease Cancer's lingering toll?